Volume 30, Number 8—August 2024
    
    Research
Fatal SARS-CoV-2 Infection among Children, Japan, January–September 20221
Table 2
Results of examinations, drugs, and treatments after hospitalization for 27 patients in study of fatal SARS-CoV-2 infection among patients 0–19 years of age, Japan, January–September 2022*
| Result | No. (%) patients | 
| Pathogen detected in blood culture† | |
| Streptococcus spp. | 2 (7) | 
| Escherichia spp. | 1 (4) | 
| Fusobacterium spp. | 1 (4) | 
| Chest CT findings‡ | |
| Ground-glass opacity | 5 (21) | 
| Consolidation | 5 (21) | 
| Pleural effusion | 1 (4) | 
| Brain CT findings§ | |
| Cerebral edema | 14 (40) | 
| Loss of gray-white matter differentiation | 7 (20) | 
| Intracranial hemorrhage | 3 (9) | 
| Hydrocephalus | 3 (9) | 
| Congenital abnormalities | 3 (9) | 
| Drug† | |
| Inotrope | 16 (59) | 
| Steroid | 14 (52) | 
| Antiviral | 12 (44) | 
| Treatment† | |
| Mechanical ventilation | 23 (85) | 
| Extracorporeal membrane oxygenation | 5 (19) | 
| Targeted temperature management | 4 (15) | 
| Blood transfusion | 13 (48) | 
| Immune globulin | 4 (15) | 
| Dialysis | 3 (11) | 
| Plasmapheresis | 1 (4) | 
*CT, computed tomography. †Includes multiple pathogens, drugs, and treatments. ‡Includes multiple findings; 24 cases involving chest CT are included. §Includes multiple findings; 35 cases involving head CT are included.
1Preliminary results from this study were presented in Japanese as a government surveillance report at https://www.niid.go.jp/niid/ja/2019-ncov/2559-cfeir/11727-20.html.
2These first authors contributed equally to this article.
3Members of the COVID-19 Fatal Pediatric Cases Database Group who contributed data are listed at the end of this article.
